Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer

2018236 citationsJournal Article

Authors

CLDN18.2-specific CAR T cells could be a promising treatment strategy for gastric cancer and potentially other CLDN18.2-positive tumors.

Good health and well-being

Published in: JNCI Journal of the National Cancer Institute

Volume 111, Issue 4, pp. 409-418

Field-Weighted Citation Impact: 4.63